Zealand Pharma — August 2022
-
Zealand Pharma Announces Financial Results for the First Half of 2022
"Net operating expenses in 2022 are expected to be DKK 1,000 million +/-10%. This is unchanged from our updated guidance issued on March 30, 2022 and is a decrease of DKK 200 million from the guidance issued on March 10, 2022."
-
ude nu
-
Zealand Pharma Announces Financial Results for the First Half of 2022
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK...
GlobeNewswire News Room (www.globenewswire.com)
-
Zealand Pharma - Interim report for H1 2022 https://www.proinvestor.com/boards/105204
-
Zealand Pharmas underskud vokser i kvartal med frasalg
"Zealand Pharma skruer ned forventningerne til indtægten fra nødpennen Zegalogue."
Zealand Pharmas underskud vokser i kvartal med frasalg
Zealand Pharma skruer ned forventningerne til indtægten fra nødpennen Zegalogue.
(medwatch.dk)
-
CC omkring Zegalogue partnerskab: "We are in advanced discussions and hope to give an update soon"
-
tak god input
-
Enig Exitnu.
-
Spørgsmål til Q&A kan stilles nu.
-
Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q2 2022 Results - Earnings Call Transcript
Company Participants
Anna Krassowska - VP of IR and Corporate Communications
Adam Steensberg - President and CEO
Matt Dallas - SVP and CFO
David Kendall - Chief Medical Officer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind